Based on our in vitro study that RAD54B enhances p53 protein degradation via the MDM2–MDMX ubiquitin–ligase complex [13], we analyzed CDKN1A expression, a target gene of p53, to elucidate the biological role of RAD54B in clinical CRC tissues. Here, MDM2 is linked to colorectal carcinoma.